Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
1.435
+0.035 (2.50%)
Nov 21, 2024, 12:08 PM EST - Market open
Salarius Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
2.07M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Xylo Technologies | 57.64M |
Scorpius Holdings | 10.04M |
Akanda | 2.51M |
Biodexa Pharmaceuticals | 104.90K |
Sonnet BioTherapeutics Holdings | 55.88K |
SLRX News
- 5 months ago - Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split - GlobeNewsWire
- 8 months ago - Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 11 months ago - Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment - GlobeNewsWire
- 1 year ago - Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire